Aerosolized dornase alpha (rhDNase) in cystic fibrosis.

Aerosolized dornase alpha (rhDNase) in cystic fibrosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Aerosolized dornase alpha (rhDNase) in cystic fibrosis. Abstract Text:

Advances in the treatment and management of respiratory and pancreatic disorders has increased the life expectancy of patients with cystic fibrosis to 28 years (1). Despite the use of potent antibiotics and chest physiotherapy, persistent bacterial infection of the lung is the major cause of morbidity and mortality in these patients (2). This occurs, in part, because of the production of copious amounts of pulmonary secretions. It has been found that these secretions contain high amounts of human DNA (3-8). This high DNA concentration causes two problems. First, it increases the viscosity of sputum. This, in conjunction with reduced mucociliary clearance, decreases the removal of sputum. Second, the DNA binds to aminoglycosides, which decreases their antimicrobial efficacy (9, 10). Until recently there was no effective drug to decrease the viscosity of sputum in patients with cystic fibrosis. Dornase alpha (Pulmozyme) is the first drug to offer a safe and effective method to treat excessive DNA in sputum. In vitro studies demonstrated that rhDNase greatly decreased the viscosity of sputum by decreasing the concentration of DNA in a concentration-dependent manner (11).

Aerosolized dornase alpha (rhDNase) in cystic fibrosis. Publishing Authors By Initials

For similar proteins: recombinant proteins research abstracts see: proteins: recombinant proteins research

PUBMED ID PMID:

MEDLINE DATE:

Aerosolized dornase alpha (rhDNase) in cystic fibrosis. Journal Published:

PUBLICATION TYPE: Review

Journal: Journal of clinical pharmacy and therapeutics

VOLUME: 20

Page Numbers: 313-5

Journal Abbreviation: J Clin Pharm Ther

ISSN: 0269-4727

DAY: 28

MONTH: Dec

YEAR: 1995

Aerosolized dornase alpha (rhDNase) in cystic fibrosis. Information

Number of References: 19

LANGUAGE: eng

NlmUniqueID: 8704308

Aerosolized dornase alpha (rhDNase) in cystic fibrosis. Keywords Mesh Terms:

KEYWORDS: Recombinant Proteins

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Aerosolized dornase alpha (rhDNase) in cystic fibrosis. Information

Substance Name: Deoxyribonuclease I

Registry Number: EC 3.1.21.1

Grant and Affiliation Information for Aerosolized dornase alpha (rhDNase) in cystic fibrosis.

AFFILIATION: College of Pharmacy, Ohio State University, Columbus 43210, USA.

Country: ENGLAND

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Clin Pharm Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Aerosolized dornase alpha rhDNase in cystic fibrosis Related Publications

• A comparative review of conventional and lipid formulations of amphotericin B.
• A programme to enrich undergraduate education through participation in clinical pharmacy research.
• Advances in paediatric pharmacotherapy.
• Aerosolized dornase alpha (rhDNase) in cystic fibrosis.
• Clinical research by pharmacists.
• Clinical uses of dexmedetomidine in pediatric patients.
• Cognitive effects of atypical antipsychotics in patients with Alzheimer's disease and comorbid psychiatric or behavioral problems: a retrospective study.
• Do statins slow down Alzheimer's disease? A review.
• Drug administration errors in pediatric patients.
• Drug combinations in India.
• Electro-optic detection of continuous-wave mid-infrared radiation.
• Electro-optic detection of femtosecond electromagnetic pulses by use of poled polymers.
• Extended stability of iobenguane under simulated clinical conditions.
• Extraordinary optical transmission through metallic films perforated with aperture arrays having short-range order.
• Generation of broadband radially polarized terahertz radiation directly on a cylindrical metal wire.
• Guidelines for antimicrobial prophylaxis.
• Lack of predictability of chloramphenicol toxicity in paediatric patients.
• Long-term effects of antidepressants on cognition in patients with Alzheimer's disease.
• Nonlinear optical generation and detection of ultrashort electrical pulses in transmission lines.
• Paediatric drug therapy. I--Medication use in hospitalized patients.
• Paediatric drug therapy. II--Drug administration errors.
• Pharmacotherapy of lower limb diabetic ulcers.
• Planar plasmonic terahertz guided-wave devices.
• Plasma concentrations of morphine in children with chronic pain--comparison of controlled release and regular morphine sulphate tablets.
• Prospective evaluation of ten methods for estimating creatinine clearance in children with varying degrees of renal dysfunction.
• Recent advances in the treatment of otitis media.
• Simultaneous measurement of chloramphenicol sodium succinate and chloramphenicol in presence of furosemide in plasma and urine.
• Teaching paediatric pharmacotherapy at colleges of pharmacy in the United States and Canada.
• Tips for writing and publishing an article.
• Variability in clinical pharmacology of drugs in children.